Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOUT: 18F-rhPSMA-7.3 in Prostate Cancer After Focal Gland Treatment
NCT07011342Recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Oct 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by Hackensack Meridian Health. Primary endpoint: Effectiveness of PSMA-PET scan in identifying recurrent prostate cancer at 1 year. Started Oct 2025; status: recruiting.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07011342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011342.